Walleye Capital’s Pacific Biosciences PACB Stock Holding History

Walleye Capital’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,943,046	Closed	-$3.56M	–	4897
2024 Q4	$3.56M	Buy	1,943,046 +1,698,931	+696%	+$3.32M	0.01%	1313
2024 Q3	$415K	Buy	244,115 +89,484	+58%	+$147K	﹤0.01%	3474
2024 Q2	$212K	Buy	154,631 +148,209	+2,308%	+$299K	﹤0.01%	4263
2024 Q1	$24.1K	Sell	6,422 -31,323	-83%	-$183K	﹤0.01%	4879
2023 Q4	$370K	Buy	+37,745	New	+$309K	﹤0.01%	3183
2022 Q2	–	Sell	-51,225	Closed	-$466K	–	2631
2022 Q1	$466K	Buy	51,225 +41,272	+415%	+$475K	0.01%	1045
2021 Q4	$204K	Buy	+9,953	New	+$240K	0.01%	1464
2021 Q3	–	Sell	-6,100	Closed	-$213	–	1749
2021 Q2	$213	Buy	+6,100	New	+$177K	0.01%	1048
2020 Q4	–	Sell	-19,720	Closed	-$195K	–	1069
2020 Q3	$195K	Buy	19,720 +9,720	+97%	+$56K	0.02%	620
2020 Q2	$35K	Buy	+10,000	New	+$34K	0.01%	560

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Walleye Capital's PACB Position: Q1 2025 in Review

Walleye Capital sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 1,943,046 shares — an estimated $3.56M sold.

Walleye Capital first reported a position in PACB in Q2 2020 and held it in 10 quarters. The position peaked at $3.56M in Q4 2024. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

Walleye Capital reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 1,943,046 Pacific Biosciences shares in Q1 2025, an estimated $3.56M.
Walleye Capital first reported a position in Pacific Biosciences in Q2 2020 and held it in 10 quarters.
Walleye Capital's Pacific Biosciences position peaked at $3.56M in Q4 2024.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.